Meeting
2016 ASCO Annual Meeting
The DETECT study concept: Individualized therapy of metastatic breast cancer.
Authors
Arkadius Polasik
University Hospital Ulm, Department of Gynecology and Obstetrics, Ulm, Germany
Arkadius Polasik , Amelie Schramm , Thomas W. P. Friedl , Brigitte Kathrin Rack , Elisabeth Katharina Trapp , Peter A. Fasching , Florin-Andrei Taran , Andreas D. Hartkopf , Andreas Schneeweiss , Volkmar Mueller , Bahriye Aktas , Klaus Pantel , Franziska Meier-Stiegen , Pauline Wimberger , Wolfgang Janni , Tanja N. Fehm
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT01619111, NCT 02035813, NCT02344472
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS634)
DOI
10.1200/JCO.2016.34.15_suppl.TPS634
Abstract #
TPS634
Poster Bd #
111b
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
The DETECT Study Program: Personalized treatment in advanced breast cancer based on circulating tumor cells (CTCs).
First Author: Amelie Schramm
Poster
2014 ASCO Annual Meeting
DETECT III/IV: Two combined clinical trials based on the phenotype of circulating tumor cells (CTCs).
First Author: Susanne Albrecht
Poster
2018 ASCO Annual Meeting
Analysis of circulating tumor cells (CTCs) in patients across multiple metastatic breast cancer (mBCa) cohorts identifies marked inter- and intra-patient heterogeneity in CTC size, shape, and overall morphology.
First Author: Gordon Vansant
Poster
2017 ASCO Annual Meeting
A phase II, multicenter, randomized trial of eribulin plus gemcitabine (EG) vs. paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer (MBC) as first-line chemotherapy (KCSG BR13-11, NCT02263495).
First Author: Kyung Hae Jung